RNTX Earnings Date: Nov 13, 2026 (Estimated) — Rein Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is RNTX's next earnings date?
Rein Therapeutics Inc. (RNTX) is expected to report Q3 2026 earnings on Friday, November 13, 2026 at 8:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.10.
How did RNTX do in its last earnings report?
In its most recent report on Aug 14, 2026 (Q2 2026), Rein Therapeutics Inc. posted EPS of -$0.10 versus the -$0.17 estimate, a beat of 47.4%. Revenue was $0. The stock's 1-day post-earnings move was +2.3%.
How much does RNTX stock move after earnings?
RNTX beat EPS estimates in 5 of its last 7 reported quarters. Over the last 8 reports the stock moved an average of 7.6% (up or down) in the day after earnings.
About Rein Therapeutics Inc.
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-14 | Q2 2026 | -0.17 | -0.10 | +47.37% | $0 | ✅ Beat | +2.35% | +0.77% | +0.44% |
| 2026-05-15 | Q1 2026 | -0.49 | -0.19 | +61.22% | $0 | ✅ Beat | -7.08% | -7.96% | -16.59% |
| 2026-03-26 | Q4 2025 | -0.23 | -0.11 | +52.17% | $0 | ✅ Beat | -1.57% | -4.72% | +17.32% |
| 2025-11-14 | Q3 2025 | -0.24 | -0.21 | +12.50% | $0 | ✅ Beat | -7.41% | +2.22% | +9.63% |
| 2025-08-14 | Q2 2025 | -0.22 | -0.28 | -27.27% | $0 | ❌ Miss | +3.38% | -2.16% | -3.90% |
| 2025-04-07 | Q4 2024 | — | -1.89 | — | $0 | — | -15.24% | +1.22% | -0.61% |
| 2024-11-14 | Q3 2024 | -0.41 | -0.27 | +34.15% | $0 | ✅ Beat | -13.29% | -22.05% | -35.95% |
| 2024-08-14 | Q2 2024 | -0.42 | -0.45 | -7.14% | $0 | ❌ Miss | -10.81% | +38.38% | +48.11% |
Showing last 8 quarters.